Recursion
Techbio company using AI and massive biological datasets to discover drugs - AI cell biology platform for drug candidate identification.
What it does
Recursion Pharmaceuticals is a techbio company that combines AI, massive biological datasets, and laboratory automation to accelerate drug discovery - operating one of the world's largest biological imaging datasets and using AI to identify drug candidates. Recursion's OS (operating system) platform enables partnerships with pharmaceutical companies to apply AI-driven biological experimentation to specific disease programs. AI capabilities include deep learning biological image analysis that identifies cellular phenotypes from high-content imaging experiments, ML drug-disease interaction prediction that identifies promising drug-target combinations from biological data, AI compound activity prediction that ranks molecules by likelihood of therapeutic effect, multi-omics data integration that correlates genetic, transcriptomic, and phenotypic datasets for drug mechanism understanding, and automated experimental design that plans efficient biological experiments.
Why AI-NATIVE
Recursion is AI-native - deep learning biological image analysis and AI-driven drug candidate identification from massive biological datasets are the core product architecture.
Best for
Large pharmaceutical companies partner with Recursion for AI drug discovery programs - applying Recursion's AI biological platform and datasets to specific therapeutic area programs.
Limitations
Recursion operates as a drug discovery company using AI rather than selling AI drug discovery software — pharmaceutical companies engage Recursion through partnerships rather than licensing software.
Recursion's AI-discovered candidates must progress through clinical trials before validating the platform's ability to identify successful drugs — AI drug discovery remains an emerging capability rather than proven approach.
Multiple AI-first drug discovery companies compete in this space — pharmaceutical partners evaluate biological data breadth, AI model accuracy, and clinical track record when selecting AI drug discovery collaborators.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| AI drug design software platform | Schrodinger |
| AI drug discovery collaboration | Exscientia |
| Computational biology drug discovery | Iktos |
Recursion operates through research collaborations and partnerships. Commercial partnership terms negotiated with pharmaceutical companies.
